FV-100: antiviral; potent and selective inhibitors of varicella zoster virus; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 71587897 |
| CHEMBL ID | 4297380 |
| MeSH ID | M0518593 |
| Synonym |
|---|
| fv-100 |
| 956483-03-7 |
| l4n5f436fo , |
| unii-l4n5f436fo |
| l-valine, 5'-ester with 3-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo(2,3-d)pyrimidin-2(3h)-one hydrochloride |
| valnivudine hydrochloride |
| fv100 |
| DTXSID40241910 |
| Q27282701 |
| CHEMBL4297380 |
| (s)-((2r,3s,5r)-3-hydroxy-5-(2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3(2h)-yl)tetrahydrofuran-2-yl)methyl 2-amino-3-methylbutanoate hydrochloride |
| CS-0017004 |
| HY-19856 |
| AKOS040758494 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 4 (57.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (14.29%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cytosine | aminopyrimidine; pyrimidine nucleobase; pyrimidone | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| valine | L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 2017 | 2017 | 7.0 | medium | 1 | 0 | 0 | 0 | 1 | 0 | |
| organophosphonates | divalent inorganic anion; phosphite ion | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| cmx 001 | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| acyclovir | 2-aminopurines; oxopurine | antimetabolite; antiviral drug | 2017 | 2017 | 7.0 | medium | 1 | 0 | 0 | 0 | 1 | 0 | |
| valacyclovir | L-valyl ester | antiviral drug | 2017 | 2017 | 7.0 | medium | 1 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ache | 0 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Chicken Pox | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Chickenpox | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Congenital Varicella Syndrome | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Encephalitis, Herpes Zoster | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Herpes Zoster | 1 | 2010 | 2022 | 9.0 | high | 2 | 0 | 0 | 1 | 2 | 1 | |
| Neuralgia, Postherpetic | 0 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Pain | 0 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Postherpetic Neuralgia | 0 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Recrudescence | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Shingles | 0 | 2010 | 2022 | 9.0 | high | 2 | 0 | 0 | 1 | 2 | 1 |
| Article | Year |
|---|---|
| Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrobial agents and chemotherapy, , Volume: 55, Issue:6 | 2011 |
| Article | Year |
|---|---|
| Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrobial agents and chemotherapy, , Volume: 55, Issue:6 | 2011 |
| Article | Year |
|---|---|
| FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis? Viruses, , 04-07, Volume: 14, Issue:4 | 2022 |
| FV-100: the most potent and selective anti-varicella zoster virus agent reported to date. Antiviral chemistry & chemotherapy, , Jan-05, Volume: 20, Issue:3 | 2010 |
| Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. The Journal of antimicrobial chemotherapy, , Volume: 60, Issue:6 | 2007 |
| Article | Year |
|---|---|
| Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules (Basel, Switzerland), , Feb-20, Volume: 26, Issue:4 | 2021 |
| Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrobial agents and chemotherapy, , Volume: 55, Issue:6 | 2011 |
| Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. The Journal of antimicrobial chemotherapy, , Volume: 60, Issue:6 | 2007 |